Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Asthma Clinical Trial

Official title:

A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03629249
• Other study ID #: CQAW039A2323
• Secondary ID: 2018-000212-25
• Status: Terminated
• Phase: Phase 3
• Start date: December 13, 2018
• Est. completion date: February 6, 2020

Study information

• Verified date: October 2021
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in terms of avoidance of corticosteroid use over 52 weeks.

Description:

This was a randomized, multicenter, double-blind, double-dummy, placebo-controlled, parallel-group study to determine the ability of fevipiprant (QAW039) plus standard-of-care (SoC) compared with placebo plus SoC to reduce the use of systemic corticosteroids (SCS) in patients with severe asthma. The study included:

• a Screening period of up to 2 weeks to assess eligibility;

• a Run-in period of 4 or 10 weeks to evaluate maintenance of asthma control and to collect baseline safety data. The Run-in period was 4 weeks for patients coming with high-dose ICS/LABA (inhaled corticosteroids/long-acting beta-agonist) and 10 weeks for patients switching from mid-dose to high-dose ICS/LABA as per protocol during the run-in period;

• a Treatment period of 52 weeks. Upon completion of the Run-in period, all patients who met eligibility criteria were randomized to 1 of 3 treatment groups (fevipiprant 150 mg or 450 mg or placebo once daily) in a ratio 1:1:1. Randomized patients were stratified according to their peripheral blood eosinophil count (< 250 cells/μl or ≥ 250 cells/μl);

• a Follow-up period of 2 weeks following the last dose of study drug to collect additional data for safety variables.

The main purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to GINA (Global Initiative for Asthma) treatment step 4 or 5 SoC asthma therapy in terms of avoidance of SCS use over 52 weeks in patients with inadequately controlled severe asthma and high eosinophil counts (eosinophil count at Visit 1 ≥250 cells/ μl) and in the overall patient population regardless of eosinophil counts.

On 16-Dec-2019 the sponsor decided to terminate study CQAW039A2323 earlier than the planned study completion. There were no safety findings with fevipiprant that contributed to this decision. The planned treatment period of 52 weeks was not completed by any patient; patients were treated for a median time of 14 weeks in each group and a maximum of up to 36 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 604
• Est. completion date: February 6, 2020
• Est. primary completion date: February 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 84 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of asthma for a period of at least 3 months prior to Screening Visit with current asthma severity step 4 or 5 (GINA 2018)

• Currently on treatment with medium or high dose ICS/LABA +/- other controller (i.e.long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist (LTRA) etc. as per GINA) for a minimum of 6 weeks prior to Screening Visit

• At screening, patients with FEV1 of =80% of the predicted normal value for the patient, after withholding bronchodilators at Screening Visit and beginning of Run-In Visit

• An increase of =12% and =200 ml in FEV1 approximately 10 to 15 minutes after administration of 400 mcg of salbutamol/albuterol prior to randomization (documented historical reversibility was accepted).

• Demonstration of inadequate control of asthma based on an ACQ-5 score =1.5 at Screening Visit and Treatment Day 1 Visit

• Documented history of at least 1 asthma exacerbation within 1 year prior to enrollment

Exclusion Criteria:

• Asthma exacerbation, within 6 weeks prior to enrollment (screening) that required SCS, hospitalization, or emergency room visit

• Chronic/maintenance use of oral corticosteroids (OCS) for asthma (total OCS use days greater than 6 months; continuously or intermittently) within the last year

• Prior use of biologics that has potential to interfere/ affect asthma disease progression, in the previous 6 months from run-in period.

• Any contraindications of SCS use e.g. diabetes, narrow angle glaucoma, or any other as defined by the treating physician

• Pregnant or nursing (lactating) women

• Use of other investigational drugs within 5 half-lives of enrollment, or [within 30 days], whichever is longer

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Placebo once daily
Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
• QAW039 150 mg once daily
QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
• QAW039 450 mg once daily
QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)

Locations

Country	Name	City	State
Argentina	Novartis Investigative Site	Buenos Aires
Argentina	Novartis Investigative Site	Buenos Aires
Argentina	Novartis Investigative Site	Buenos Aires
Argentina	Novartis Investigative Site	Buenos Aires
Argentina	Novartis Investigative Site	Buenos Aires
Argentina	Novartis Investigative Site	Caba
Argentina	Novartis Investigative Site	Caba	Buenos Aires
Argentina	Novartis Investigative Site	Caba	Buenos Aires
Argentina	Novartis Investigative Site	Cordoba
Argentina	Novartis Investigative Site	Florida	Buenos Aires
Argentina	Novartis Investigative Site	Mar del Plata	Buenos Aires
Argentina	Novartis Investigative Site	Rosario	Santa Fe
Argentina	Novartis Investigative Site	San Miguel de Tucuman	Tucuman
Argentina	Novartis Investigative Site	San Miguel de Tucuman	Tucuman
Belgium	Novartis Investigative Site	Erpent
Belgium	Novartis Investigative Site	Lebbeke
Belgium	Novartis Investigative Site	Liege
Belgium	Novartis Investigative Site	Mechelen
Bulgaria	Novartis Investigative Site	Pleven
Bulgaria	Novartis Investigative Site	Sofia
Bulgaria	Novartis Investigative Site	Vidin	BGR
Chile	Novartis Investigative Site	Curico	VII Region Del Maule
Chile	Novartis Investigative Site	Santiago	Region Metropolitana
Colombia	Novartis Investigative Site	Bogota
Colombia	Novartis Investigative Site	Bogota
Colombia	Novartis Investigative Site	Bucaramanga
Colombia	Novartis Investigative Site	Zipaquira	Cundinamarca
Czechia	Novartis Investigative Site	Beroun	Czech Republic
Czechia	Novartis Investigative Site	Jindrichuv Hradec
Czechia	Novartis Investigative Site	Lovosice
Czechia	Novartis Investigative Site	Praha 4	Czech Republic
Czechia	Novartis Investigative Site	Teplice	Czech Republic
Czechia	Novartis Investigative Site	Teplice	CZE
Czechia	Novartis Investigative Site	Varnsdorf
France	Novartis Investigative Site	Grenoble Cedex 9
France	Novartis Investigative Site	Lyon cedex 04	Rhone
France	Novartis Investigative Site	Montpellier cedex 5	Herault
France	Novartis Investigative Site	Pessac Cedex
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Darmstadt
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Hamburg
Germany	Novartis Investigative Site	Hamburg
Germany	Novartis Investigative Site	Hannover
Germany	Novartis Investigative Site	Koblenz	NRW
Germany	Novartis Investigative Site	Landsberg
Germany	Novartis Investigative Site	Leipzig
Germany	Novartis Investigative Site	Leipzig
Germany	Novartis Investigative Site	Leipzig
Germany	Novartis Investigative Site	Mainz
Germany	Novartis Investigative Site	Marburg
Germany	Novartis Investigative Site	Witten
Greece	Novartis Investigative Site	Athens	GR
Greece	Novartis Investigative Site	Athens	GR
Greece	Novartis Investigative Site	Heraklion Crete
Greece	Novartis Investigative Site	Thessaloniki	GR
Greece	Novartis Investigative Site	Thessaloniki	GR
Hungary	Novartis Investigative Site	Balassagyarmat
Hungary	Novartis Investigative Site	Godollo
Hungary	Novartis Investigative Site	Gyor	HUN
Hungary	Novartis Investigative Site	Hajdunanas	HUN
Hungary	Novartis Investigative Site	Kapuvár	HUN
Hungary	Novartis Investigative Site	Nyiregyhaza
Hungary	Novartis Investigative Site	Pecs
Hungary	Novartis Investigative Site	Puspokladany	HUN
Hungary	Novartis Investigative Site	Szazhalombatta	HUN
Hungary	Novartis Investigative Site	Szeged
Peru	Novartis Investigative Site	Cusco
Peru	Novartis Investigative Site	Lima
Peru	Novartis Investigative Site	Piura
Peru	Novartis Investigative Site	San Isidro	Lima
Philippines	Novartis Investigative Site	Iloilo
Philippines	Novartis Investigative Site	Iloilo city	Iloilo
Philippines	Novartis Investigative Site	Iloilo City
Philippines	Novartis Investigative Site	Lipa City	Batangas
Russian Federation	Novartis Investigative Site	Barnaul
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Petrozavodsk
Russian Federation	Novartis Investigative Site	Saint Petersburg
Russian Federation	Novartis Investigative Site	Saint-Petersburg
Russian Federation	Novartis Investigative Site	Saratov
Russian Federation	Novartis Investigative Site	St Petersburg
Russian Federation	Novartis Investigative Site	St Petersburg
Russian Federation	Novartis Investigative Site	Stavropol
Russian Federation	Novartis Investigative Site	Volgograd
Slovakia	Novartis Investigative Site	Bardejov	Slovak Republic
Slovakia	Novartis Investigative Site	Humenne	Slovak Republic
Slovakia	Novartis Investigative Site	Levice	Slovak Republic
Slovakia	Novartis Investigative Site	Spisska Nova Ves	Slovak Republic
Slovakia	Novartis Investigative Site	Zilina
South Africa	Novartis Investigative Site	Berea	Durban
South Africa	Novartis Investigative Site	Cape Town
Spain	Novartis Investigative Site	Badalona	Catalunya
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Marbella	Andalucia
Spain	Novartis Investigative Site	Santiago de Compostela
Thailand	Novartis Investigative Site	Bangkok
Turkey	Novartis Investigative Site	Mersin
United Kingdom	Novartis Investigative Site	Bradford	West Yorkshire
United Kingdom	Novartis Investigative Site	Chertsey	Surrey
United Kingdom	Novartis Investigative Site	Portsmouth	Hants
United States	Novartis Investigative Site	Bangor	Maine
United States	Novartis Investigative Site	Boerne	Texas
United States	Novartis Investigative Site	Bronx	New York
United States	Novartis Investigative Site	Dallas	Texas
United States	Novartis Investigative Site	McKinney	Texas
United States	Novartis Investigative Site	Newport Beach	California
United States	Novartis Investigative Site	Waldorf	Maryland
United States	Novartis Investigative Site	Westminster	California
United States	Novartis Investigative Site	Winter Park	Florida
Vietnam	Novartis Investigative Site	Hanoi
Vietnam	Novartis Investigative Site	Hanoi
Vietnam	Novartis Investigative Site	Ho Chi Minh

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Vietnam,  Argentina,  Belgium,  Bulgaria,  Chile,  Colombia,  Czechia,  France,  Germany,  Greece,  Hungary,  Peru,  Philippines,  Russian Federation,  Slovakia,  South Africa,  Spain,  Thailand,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Systemic Corticosteroid Dose in mg Prednisone/Prednisolone or Equivalent Over 52 Weeks in the Overall Population	All participants were provided with prednisone/prednisolone (or equivalent) tablets that could be used according to the asthma plan along with an electronic diary (e-Diary/ePEF). Daily use of oral corticosteroids (number of tablets taken in the previous 12 hours) was recorded once in the morning and once in the evening by the subject in the eDiary/PEF device. In case of use of injectable corticosteroids during certain circumstances (eg. hospitalization) the data was collected on the eCRF (electronic case report form).; The total systemic corticosteroids (SCS) dose data was aggregated into monthly data for analysis. For the patients discontinuing treatment early, the total SCS dose for 52 weeks was obtained as annualized SCS dose. For example if patient took 120 mg for 3 months then for 12 months patient will be taking 120*12/3=480mg total SCS dose.; The mean values over 52 weeks in the overall patient population regardless of peripheral blood eosinophil counts are reported here.	52 weeks
Primary	Total Systemic Corticosteroid Dose in mg Prednisone/Prednisolone or Equivalent Over 52 Weeks in the Subpopulation of Patients With High Eosinophil Count (= 250 Cells/µl)	All participants were provided with prednisone/prednisolone (or equivalent) tablets that could be used according to the asthma plan along with an electronic diary (e-Diary/ePEF). Daily use of oral corticosteroids (number of tablets taken in the previous 12 hours) was recorded once in the morning and once in the evening by the subject in the eDiary/PEF device. In case of use of injectable corticosteroids during certain circumstances (eg. hospitalization) the data was collected on the eCRF (electronic case report form).; The total systemic corticosteroids (SCS) dose data was aggregated into monthly data for analysis. For the patients discontinuing treatment early, the total SCS dose for 52 weeks was obtained as annualized SCS dose. For example if patient took 120 mg for 3 months then for 12 months patient will be taking 120*12/3=480mg total SCS dose.; The mean values over 52 weeks in the subpopulation of patients with high peripheral blood eosinophil count at baseline are reported here.	52 weeks
Secondary	Change From Baseline in Daytime Symptom Scores	All participants were provided with an electronic diary (eDiary/ePEF) to record asthma symptom twice per day. Daytime asthma symptoms were assessed before bed and nighttime asthma symptoms on awakening.; The daytime asthma symptom score included 4 questions with a range of response categories for each question from 0 to 6 (0 = totally controlled; 6 = extremely poorly controlled). The questions were equally weighted and the overall score (from 0 to 6) was calculated as the average of the 4 questions with higher values indicating more asthma symptoms.; Mean values of daytime asthma symptom scores were calculated over 4-week intervals during the treatment period.; The baseline values of daytime asthma symptoms scores were defined as the average score during the run-in period.; A negative change from baseline in daytime asthma symptom score is a favorable outcome.	Baseline, up to Week 29-32
Secondary	Change From Baseline in Nighttime Symptom Scores	All participants were provided with an electronic diary (eDiary/ePEF) to record asthma symptom twice per day. Daytime asthma symptoms were assessed before bed and nighttime asthma symptoms on awakening.; The nighttime asthma symptom score included 1 question with a range of response categories from 0 to 3 (0 = no awakening with asthma symptoms; 3 = awake all night).; Mean values of nighttime asthma symptom scores were calculated over 4-week intervals during the treatment period.; The baseline values of nighttime asthma symptoms scores were defined as the average score during the run-in period.; A negative change from baseline in nighttime asthma symptom score is a favorable outcome.	Baseline, up to Week 29-32
Secondary	Change From Baseline in ACQ-5 Total Score up to End of Treatment Visit	The Asthma Control Questionnaire (ACQ-5) was completed by the patients at the investigator's site. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions were equally weighted and the ACQ-5 score was the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).; The baseline values of ACQ-5 score were defined as the ACQ-5 scores obtained on Day 1.; A negative change from baseline in ACQ-5 score is a favorable outcome.	Baseline, up to Week 28
Secondary	Change From Baseline in AQLQ+12 Total Score up to End of Treatment Visit	The Asthma Quality of Life Questionnaire (AQLQ+12) was completed by the patients at the investigator's site. The AQLQ+12 is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma. Patients were asked to recall their experiences during the previous 2 weeks and to score each of the 32 items on a 7-point scale, where 1 indicates maximal impairment and 7 indicates no impairment. Thus, higher scores indicate better asthma-related quality of life. Each item of the AQLQ+12 was equally weighted and the overall score was the mean score of all 32 items and therefore ranged between 1 and 7.; The baseline values of AQLQ+12 score were defined as the AQLQ+12 scores obtained on Day 1.; A positive change from baseline in AQLQ+12 score is a favorable outcome.	Baseline, up to Week 28
Secondary	Percentage of Patients Requiring = 7.5 mg Systemic Corticosteroid Dose in mg Prednisone/Prednisolone or Equivalent Per Day Continuously for at Least 30 Days	All participants were provided with prednisone/prednisolone (or equivalent) tablets that could be used according to the asthma plan along with an electronic diary (e-Diary/ePEF) to record medication use. Daily use of oral corticosteroids (the number of tablets taken in the previous 12 hours) was recorded once in the morning and once in the evening by the subject using the eDiary/PEF device. In case of use of injectable corticosteroids during certain circumstances (eg. hospitalization) the data was collected on the eCRF (electronic case report form).; The percentage of patients requiring = 7.5 mg systemic corticosteroid dose in mg prednisone/prednisolone (or equivalent) per day continuously for at least 30 days within the on-treatment period is presented in this record.	Up to 36 weeks
Secondary	Percentage of Patients With no Systemic Corticosteroids Use	All participants were provided with prednisone/prednisolone (or equivalent) tablets that could be used according to the asthma plan along with an electronic diary (e-Diary/ePEF) to record medication use. Daily use of oral corticosteroids (the number of tablets taken in the previous 12 hours) was recorded once in the morning and once in the evening by the subject using the eDiary/PEF device. In case of use of injectable corticosteroids during certain circumstances (eg. hospitalization) the data was collected on the eCRF (electronic case report form).; The percentage of patients with no systemic corticosteroids use up to visit on Week 36 is presented in this record.	Week 36
Secondary	Percentage of Patients With Prescription of Biologic Therapy	As part of the flexible therapy, investigators were allowed to prescribe biologics approved for asthma from randomization visit onwards. Prescription of biologic therapy during the treatment period was recorded.; The proportion of patients with prescription of biologic therapy during the on-treatment period is presented in this record.	Up to 36 weeks

External Links

•   A Plain Language Trial Summary is available on novartisclinicaltrials.com